Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  bevacizumab
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 803 for your search:
Start Over
A Study of Avastin With Chemotherapy for Treatment of Metastatic or Advanced and Unresectable Colorectal Adenocarcinoma
Phase: Phase IV
Type: Natural history/Epidemiology, Treatment
Status: Completed
Age: Age not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: AVF2941n, NCT00097578
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML18527, NCT00121836
A Study of Avastin in Combination With Chemotherapy for Treatment of Colorectal Cancer and Non-Small Cell Lung Cancer (ARIES)
Phase: Phase IV
Type: Natural history/Epidemiology
Status: Completed
Age: Not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: AVF3991n, NCT00388206
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MO19390, NCT00451906
OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum.
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML21380, NCT00577031
A Study of Avastin With Taxane Therapy in Patients With Triple Negative Breast Cancer
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML22780, 2009-014279-37, NCT01094184
A Translational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ASCENT)
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML25753, NCT01588990
A Study of Avastin (Bevacizumab) in Combination With 5-FU Based Doublet Chemotherapy in Patients With Colorectal Cancer And Previously Untreated Unresectable Liver-Only Metastases
Phase: Phase IV
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML28419, NCT01695772
Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: MITO-16 - MANGO-OV2, 2012-003043-29, NCT01706120
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 04458, P30CA082103, UCSF-04458, NCT00227617
The MAX Study: Mitomycin C, Avastin and Xeloda in Patients With Untreated Metastatic Colorectal Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: AG0501CR, NCT00294359
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D8480C00013, Eudract Number 2005-003440-66, NCT00384176
Mesothelioma Avastin Plus Pemetrexed-cisplatin Study
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor: Other
Protocol IDs: IFCT-GFPC-0701, NCT00651456
Combination Chemotherapy and Bevacizumab With or Without Bevacizumab Maintenance Therapy in Treating Patients With Metastatic Colorectal Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000636983, FFCD-PRODIGE-9, FFCD-0802, EU-20912, EU-21030, EUDRACT-2008-007928-25, EUDRACT-2009-017996-11, FFCD-PRODIGE 9/ FFCD 0802, NCT00952029
Bevacizumab in Extensive Small Cell Lung Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 to 75
Sponsor: Other
Protocol IDs: IFCT-0802, 2009-010187-42, NCT00930891
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02947, E4599, U10CA021115, CDR0000068744, ECOG-4599, CALGB-E4599, NCT00021060
Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 3 to 21
Sponsor: NCI
Protocol IDs: NCI-2011-02616, CDR0000688443, ACNS0822, U10CA098543, COG-ACNS0822, NCT01236560
Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: GBG 66, 2011-000553-23, NCT01426880
Phase III Randomized Study of Bevacizumab With Capecitabine Versus Capecitabine Alone in Women With Previously Treated Metastatic Breast Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: GENENTECH-AVF2119g, GUMC-00299, MSKCC-01008, UAB-0028, UAB-F001009003, NCT00012285
Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02417, E3200, U10CA021115, CDR0000068951, NCT00025337
Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000335292, U10CA031946, CALGB-90206, CAN-NCIC-REC1, ECOG-CALGB-90206, REC1, NCT00072046
A Study of Capecitabine (Xeloda) as a First-line Therapy in Patients With Metastatic Colorectal Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: NO16966, NCT00069095
Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02960, CALGB-80303, CDR0000377542, U10CA031946, ECOG-80303, NCT00088894
Start Over